Legend Biotech Co. (NASDAQ: LEGN) had its price target raised by analysts at Royal Bank of Canada from $85.00 to $86.00. They now have an "outperform" rating on the stock.
Legend Biotech GAAP EPS of -$0.16 beats by $0.02, revenue of $93.99M misses by $47.37M [Seeking Alpha]
Legend Biotech Reports First Quarter 2024 Results and Recent Highlights
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.